NSE · BMLL
Bio Medica Laboratories Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹38 Cr with net profit ₹10 Cr — a 25.56% net margin, versus 16.28% the period before.
Shareholding
As of 2026-05-31
- Promoter67.7%
- Public29.71%
- FII0.29%
- DII2.31%
1,195 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.6× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #1 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,86,768 Cr | 85.22 | 22.21 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,559 Cr | 159.56 | 9.43 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,774 Cr | 113.76 | 4.03 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹24,759 Cr | 100.34 | 19.21 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,619 Cr | 115.33 | 5.47 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹18,817 Cr | 65.92 | 4.82 | 15.87% | 19.89% |
| Marksans Pharma Limited | ₹11,850 Cr | 28.36 | 3.92 | 13.82% | 14.16% |
| Shilpa Medicare Ltd. | ₹11,827 Cr | 50.69 | 4.56 | 9.39% | 15.81% |
| Senores Pharmaceuticals Limited | ₹5,917 Cr | 46.82 | 6.34 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,799 Cr | 140.53 | 4.01 | 8.95% | 11.15% |
| Bio Medica Laboratories Limited(this company) | — | 0 | 3.25 | 66.48% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashBio Medica Laboratories Limited (BMLL) is listed under the Pharmaceuticals sector. The company reported a Return on Equity (ROE) of 66.48% and a Return on Capital Employed (ROCE) of 62.9%. The book value per share is Rs 49.24. As of May 31, 2026, promoters held 67.6971% of the shares.
Positives
- +Revenue increased from Rs 15.3443 Cr in Mar 2024 to Rs 38.325 Cr in Mar 2025.
- +Net profit increased from Rs 2.4987 Cr in Mar 2024 to Rs 9.7949 Cr in Mar 2025.
- +The company has a high Return on Equity (ROE) of 66.48% and Return on Capital Employed (ROCE) of 62.9%.
- +Earnings Per Share (EPS) increased significantly from Rs 2.72 in Mar 2024 to Rs 10.67 in Mar 2025.
- +Promoter holding is substantial at 67.6971% as of May 31, 2026.
Negatives
- −The debt-to-equity ratio is 1.3.
- −The PE ratio is 0, indicating either no earnings or a very low price relative to earnings, which requires further investigation.
- −No quarterly results have been disclosed.
Financial Performance
Bio Medica Laboratories Limited's revenue increased from Rs 15.3443 Cr in Mar 2024 to Rs 38.325 Cr in Mar 2025. Net profit also rose from Rs 2.4987 Cr in Mar 2024 to Rs 9.7949 Cr in Mar 2025. Earnings Per Share (EPS) saw an increase from Rs 2.72 in Mar 2024 to Rs 10.67 in Mar 2025.
Profitability & Returns
The company demonstrated a Return on Equity (ROE) of 66.48% and a Return on Capital Employed (ROCE) of 62.9%. The Earnings Per Share (EPS) was reported as Rs 10.67 as of Mar 2025. The company currently has a PE ratio of 0.
Balance Sheet
Bio Medica Laboratories Limited has a debt-to-equity ratio of 1.3. The book value per share is Rs 49.24. Specific detailed breakdowns of assets and liabilities beyond these figures are not available in the provided data.
Ownership & Pledges
As of May 31, 2026, promoter holding in Bio Medica Laboratories Limited stood at 67.6971%. Public shareholding was 29.7104%, while DIIs held 2.3062% and FIIs held 0.2863%. There are no promoter pledges reported for the latest period.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: May 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Bio Medica Laboratories Limitedshare price & fundamentals